FDA Approval: Brentuximab vedotin (Adcetris) for Lymphoma

A letter dated August 19, 2011

The FDA approval letter for Adcetris runs to several pages of manufacturing detail. Two sentences in it mattered to patients. The drug was approved for Hodgkin lymphoma after a stem cell transplant had failed. It was also approved for people who could not have a transplant and had already tried at least two chemotherapy regimens. A second use was named as well. It covered systemic anaplastic large cell lymphoma after at least one prior regimen.

Both were small groups with few options left. The header on the letter read "BLA ACCELERATED APPROVAL."

The idea behind the drug

Brentuximab vedotin is an antibody-drug conjugate, often shortened to ADC. Think of it as two parts joined by a chemical linker.

The first part is an antibody aimed at CD30, a protein on the surface of certain lymphoma cells. FDA's label says CD30 sits on the cells of both lymphomas named above. It also says healthy tissue carries little of it. That gap is the whole point.

The second part is MMAE, short for monomethyl auristatin E. It breaks up microtubules, the scaffolding a cell needs to divide. On its own it would be far too toxic to give.

Joined together, the antibody finds a CD30 cell. It is pulled inside. The linker is cut and the drug is set free. The cell's scaffolding collapses and the cell dies. It is chemotherapy with a delivery address. Our page on targeted therapy covers the wider family this belongs to.

What the evidence actually was

Neither use rested on a randomized trial. Each rested on one single-arm phase 2 study. That means everyone enrolled got the drug. There was no group to compare them with.

In Hodgkin lymphoma, 102 people were treated. The overall response rate was 73 percent. That was 32 percent complete remissions and 40 percent partial ones. Responses lasted 6.7 months at the midpoint. For those in complete remission the figure was 20.5 months.

In systemic anaplastic large cell lymphoma, 58 people were treated. The overall response rate was 86 percent, with 57 percent complete remissions. The median duration of response was 12.6 months.

Response rate measures tumor shrinkage on scans. It is not the same as living longer. That is why the word "accelerated" appears on the letter. Such an approval lets a drug reach patients early, based on a measure that is likely to predict benefit. Follow-up trials are then required. Our explainer on clinical trial phases sets out what a phase 2 study can and cannot settle.

Where the drug sits today

Those confirmatory trials were run, and the label grew. The current FDA label lists far more uses. One is untreated stage III or IV classical Hodgkin lymphoma, given with three other drugs. Another is untreated high-risk classical Hodgkin lymphoma in children aged 2 and over. Others cover use after a transplant, several T-cell lymphomas that carry CD30, and large B-cell lymphoma that has come back.

A drug that started as a last resort became part of first-line treatment. That path took more than a decade.

The costs of the drug

The current label carries a boxed warning, the FDA's strongest. It warns about the JC virus. That infection can cause a rare brain disease known as PML, and it can be fatal.

The label lists side effects seen in 20 percent or more of people in at least one study. They include nerve damage, fatigue, nausea, diarrhea, and low white cell counts. Fever, constipation, vomiting, hair loss, weight loss, and mouth sores are on the list too. The nerve damage is called peripheral neuropathy. It is felt as numbness, tingling, or weakness in the hands and feet. It is the side effect that most often forces a dose change.

Some context on the disease

Hodgkin lymphoma is uncommon and generally responds well. About 8,920 new cases are projected in the United States for 2026 by the American Cancer Society, whose estimate SEER republishes. Five-year relative survival, which NCI measures from SEER records, is 89.3 percent for people diagnosed between 2016 and 2022. Most people with Hodgkin lymphoma never need a drug like this one. It exists for those whose disease returns.

When a swollen node needs a look

NCI lists these signs for lymphoma: swollen lymph nodes, fever, drenching night sweats, weight loss, and fatigue. Most swollen nodes come from infection and settle within two to three weeks.

Book an appointment if a node stays swollen past three weeks with no infection to explain it. Do the same if it is painless, firm, and growing. Night sweats that soak the sheets, or weight loss you did not intend, are also reasons to go. Our guide to lymphoma symptoms explains what a doctor checks first.

What this approval cannot tell you

• Single-arm trials cannot show that people lived longer. They show how many tumors shrank, and for how long they stayed smaller.
• Response figures come from 160 people in total, chosen to fit narrow entry criteria.
• The 2011 indications are not today's. Prescribing information changes; check the current label.
• CD30 status matters. These uses are defined by that protein, not by the word "lymphoma" alone.

Sources

• FDA accelerated approval letter, ADCETRIS (August 19, 2011)
• FDA prescribing information, ADCETRIS, 2011
• FDA prescribing information, ADCETRIS, 2023
• NCI: Adult Non-Hodgkin Lymphoma Treatment (PDQ) — Patient Version
• SEER Cancer Stat Facts: Hodgkin Lymphoma

How this page was made

An AI-assisted editorial system helped prepare this page. This article has not been reviewed by a healthcare professional unless a named reviewer is specifically shown. Cancer Explained is published by the National Cancer Information Foundation as a nonprofit-oriented public-interest education project. It is not a diagnostic service, does not recommend treatments, and is not for emergencies.

Found an error, a broken source link, outdated information, or wording that feels insensitive? Report it here — we log and act on material corrections.